Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis.
In order to assess the importance of interleukin 2 receptor (IL-2R)-positive activated lymphocytes and macrophages in the pathogenesis of autoimmunity, we tested the prophylactic therapeutic efficacy of an anti-IL-2R (M7/20) monoclonal antibody, which recognizes the 55-kDa subunit of the heterodimeric IL-2R in two distinct models: the nonobese diabetic mouse and the NZB x NZW F1 hybrid with lupus. Treatment with anti-IL-2R monoclonal antibody suppressed autoimmune insulitis in nonobese diabetic mice and lupus nephritis in the NZB x NZW F1 hybrid. These studies indicate that highly selective targeting to activated lymphocytes and macrophages expressing the IL-2R provides a discrete method of dampening autoimmunity.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000517:prevention & control*; D007167:Immunotherapy; D007515:Islets of Langerhans / Q000473:pathology*; D008180:Lupus Erythematosus, Systemic / Q000517:prevention & control*; D051379:Mice; D008817:Mice, Mutant Strains; D009393:Nephritis / Q000517:prevention & control; D010195:Pancreatitis / Q000473:pathology / Q000517:prevention & control*; D011971:Receptors, Immunologic / Q000276:immunology*; D015375:Receptors, Interleukin-2
D000911:Antibodies, Monoclonal; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2